Due to a significant increase in the overall survival of women with breast cancer (BC), preventing the long-term consequences of BC treatments is of the utmost importance. Treatments such as aromatase inhibitors (AI), chemotherapy (CHT), and tamoxifen (TAM) may lead to accelerated bone loss and increased fracture risk. The aim of this retrospective cohort study was to evaluate the treatment-induced fracture risk in a large cohort of postmenopausal women with or without BC. It included 4,115 women with BC and 4,115 healthy women from the Disease Analyzer database (IQVIA). Women with breast cancer were matched 1:1 to women without BC with regard to age, index year, and physician. Within 5 years of the index date, 25.3% of women with BC and 14.6% of healthy women sustained fractures. In this study, aromatase inhibitor therapy was significantly associated with a higher incidence of fractures compared to healthy women who had not undergone such therapy (HR: 3.36, p<0.001).

In conclusion, postmenopausal women with BC who receive AI treatment exhibited an increased incidence of fractures when compared to the healthy cohort, while treatment with TAM or CHT showed no such association.

由于乳腺癌（BC）妇女的整体生存率显着提高，因此预防BC治疗的长期后果至关重要。芳香酶抑制剂（AI），化学疗法（CHT）和他莫昔芬（TAM）等治疗可能导致骨质流失加速和骨折风险增加。这项回顾性队列研究的目的是评估绝经后患有或不伴有BC的大量女性因治疗引起的骨折风险。疾病分析数据库（IQVIA）包括4115名患有BC的女性和4115名健康的女性。在年龄，索引年份和医师方面，乳腺癌女性与无BC女性的比例为1：1。在索引日期的5年内，有25.3％的BC女性和14.6％的健康女性持续骨折。在这个研究中，

总之，与健康人群相比，接受AI治疗的绝经后BC妇女的骨折发生率增加，而TAM或CHT治疗则没有这种关联。